Skip to main content
Top
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

The impact of clinicopathologic and surgical factors on relapse and pregnancy in young patients (≤40 years old) with borderline ovarian tumors

Authors: Chenyan Fang, Lingqin Zhao, Xi Chen, Aijun Yu, Liang Xia, Ping Zhang

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Fertility sparing surgery has been extensively performed among patients with borderline ovarian tumors due to their age and favorable prognosis. Nevertheless, the prognosis and obstetric outcomes in these patients remain uncertain. Thus, the current study was carried out to evaluate the oncological safety and fertility benefits of different fertility sparing surgery subtypes and various clinicopathological parameters.

Methods

Young borderline ovarian tumor patients with an age of ≤40 years, who were admitted and treated in Zhejiang Cancer Hospital from January 1996 to December 2016, were enrolled in this study and reviewed retrospectively. The prognostic and obstetric effects of clinicopathological and surgical variables were evaluated using univariate/multivariate analyses and survival curves.

Results

A total of 92 eligible patients were enrolled in the analysis. Among these patients, 22 (24%) patients showed recurrence after a median follow-up of 46.5 months. Within the fertility sparing surgery group, patients at advanced stage (≥stage II), of serous type, with micropapillary and bilateral tumors were associated with a higher recurrence rate and a shorter recurrence interval. In terms of different modalities of fertility sparing surgery, adnexectomy was remarkably favored over cystectomy-including (P = 0.012); unilateral salpingo-oophorectomy had better prognosis than cystectomy and bilateral cystectomy was favored over unilateral salpingo-oophorectomy+contralateral cystectomy. Univariate Cox regression analysis indicated that the International Federation of Gynecology and Obstetrics stage (≥Stage II), the presence of bilateral and micropapillary lesions, and the application of cystectomy-including surgery were correlated with poorer disease-free survival, while the mucinous type of borderline ovarian tumors was related to improved disease-free survival. In this study, a total of 22 patients attempted to conceive and 15 (68%) of these patients achieved successful pregnancy.

Conclusions

Unilateral salpingo-oophorectomy and bilateral cystectomy should be recommended as the preferred choice of treatment for young patients with unilateral and bilateral borderline ovarian tumor who desire to preserve fertility. In addition, borderline ovarian tumor patients at advanced stage (≥stage II), of serous type, with micropapillary and bilateral tumors should pay more attention to the risk of recurrence. Therefore, these patients should choose fertility sparing surgery carefully and attempt to achieve pregnancy as soon as possible.
Literature
1.
go back to reference Hart WR. Borderline epithelial tumors of the ovary. Mod Pathol. 2005;18(Suppl 2):S33–50.CrossRef Hart WR. Borderline epithelial tumors of the ovary. Mod Pathol. 2005;18(Suppl 2):S33–50.CrossRef
2.
go back to reference Hauptmann S, Friedrich K, Redline R, Avril S. Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Arch. 2017;470:125–42.CrossRef Hauptmann S, Friedrich K, Redline R, Avril S. Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Arch. 2017;470:125–42.CrossRef
3.
go back to reference Trillsch F, Ruetzel JD, Herwig U, et al. Surgical management and perioperative morbidity of patients with primary borderline ovarian tumor (borderline ovarian tumor). J Ovarian Res. 2013;6:48.CrossRef Trillsch F, Ruetzel JD, Herwig U, et al. Surgical management and perioperative morbidity of patients with primary borderline ovarian tumor (borderline ovarian tumor). J Ovarian Res. 2013;6:48.CrossRef
4.
go back to reference Akeson M, Zetterqvist BM, Dahllof K, et al. Population-based cohort follow-up study of all patients operated for borderline ovarian tumor in western Sweden during an 11-year period. Int J Gynecol Cancer. 2008;18:453–9.CrossRef Akeson M, Zetterqvist BM, Dahllof K, et al. Population-based cohort follow-up study of all patients operated for borderline ovarian tumor in western Sweden during an 11-year period. Int J Gynecol Cancer. 2008;18:453–9.CrossRef
5.
go back to reference Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological Cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S161–92.CrossRef Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological Cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S161–92.CrossRef
6.
go back to reference Ureyen I, Karalok A, Tasci T, et al. The factors predicting recurrence in patients with serous borderline ovarian tumor. Int J Gynecol Cancer. 2016;26:66–72.CrossRef Ureyen I, Karalok A, Tasci T, et al. The factors predicting recurrence in patients with serous borderline ovarian tumor. Int J Gynecol Cancer. 2016;26:66–72.CrossRef
7.
go back to reference Helpman L, Beiner ME, Aviel-Ronen S, et al. Safety of ovarian conservation and fertility preservation in advanced borderline ovarian tumors. Fertil Steril. 2015;104:138–44.CrossRef Helpman L, Beiner ME, Aviel-Ronen S, et al. Safety of ovarian conservation and fertility preservation in advanced borderline ovarian tumors. Fertil Steril. 2015;104:138–44.CrossRef
8.
go back to reference Levine J, Canada A, Stern CJ. Fertility preservation in adolescents and young adults with cancer. J Clin Oncol. 2010;28:4831–41.CrossRef Levine J, Canada A, Stern CJ. Fertility preservation in adolescents and young adults with cancer. J Clin Oncol. 2010;28:4831–41.CrossRef
9.
go back to reference Uzan C, Nikpayam M, Ribassin-Majed L, et al. Influence of histological subtypes on the risk of an invasive recurrence in a large series of stage I borderline ovarian tumor including 191 conservative treatments. Ann Oncol. 2014;25:1312–9.CrossRef Uzan C, Nikpayam M, Ribassin-Majed L, et al. Influence of histological subtypes on the risk of an invasive recurrence in a large series of stage I borderline ovarian tumor including 191 conservative treatments. Ann Oncol. 2014;25:1312–9.CrossRef
10.
go back to reference Trope CG, Kristensen G, Makar A. Surgery for borderline tumor of the ovary. Semin Surg Oncol. 2000;19:69–75.CrossRef Trope CG, Kristensen G, Makar A. Surgery for borderline tumor of the ovary. Semin Surg Oncol. 2000;19:69–75.CrossRef
11.
go back to reference Zanetta G, Rota S, Chiari S, et al. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol. 2001;19:2658–64.CrossRef Zanetta G, Rota S, Chiari S, et al. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol. 2001;19:2658–64.CrossRef
12.
go back to reference Trillsch F, Mahner S, Woelber L, et al. Age-dependent differences in borderline ovarian tumours (borderline ovarian tumor) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROborderline ovarian tumor study. Ann Oncol. 2014;25:1320–7.CrossRef Trillsch F, Mahner S, Woelber L, et al. Age-dependent differences in borderline ovarian tumours (borderline ovarian tumor) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROborderline ovarian tumor study. Ann Oncol. 2014;25:1320–7.CrossRef
13.
go back to reference Chang C, Chen J, Chen WA, et al. Assessing the risk of clinical and pathologic factors for relapse of borderline ovarian tumours. J Obstet Gynaecol. 2017;37:233–7.CrossRef Chang C, Chen J, Chen WA, et al. Assessing the risk of clinical and pathologic factors for relapse of borderline ovarian tumours. J Obstet Gynaecol. 2017;37:233–7.CrossRef
14.
go back to reference Karlsen NMS, Karlsen MA, Hogdall E, et al. Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (borderline ovarian tumor). Gynecol Oncol. 2016;142:50–3.CrossRef Karlsen NMS, Karlsen MA, Hogdall E, et al. Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (borderline ovarian tumor). Gynecol Oncol. 2016;142:50–3.CrossRef
15.
go back to reference Loizzi V, Selvaggi L, Leone L, et al. Borderline epithelial tumors of the ovary: experience of 55 patients. Oncol Lett. 2015;9:912–4.CrossRef Loizzi V, Selvaggi L, Leone L, et al. Borderline epithelial tumors of the ovary: experience of 55 patients. Oncol Lett. 2015;9:912–4.CrossRef
16.
go back to reference Chen RF, Li J, Zhu TT, et al. Fertility-sparing surgery for young patients with borderline ovarian tumors (borderline ovarian tumors): single institution experience. J Ovarian Res. 2016;9:16.CrossRef Chen RF, Li J, Zhu TT, et al. Fertility-sparing surgery for young patients with borderline ovarian tumors (borderline ovarian tumors): single institution experience. J Ovarian Res. 2016;9:16.CrossRef
17.
go back to reference Seong SJ, Kim DH, Kim MK, Song T. Controversies in borderline ovarian tumors. J Gynecol Oncol. 2015;26:343–9.CrossRef Seong SJ, Kim DH, Kim MK, Song T. Controversies in borderline ovarian tumors. J Gynecol Oncol. 2015;26:343–9.CrossRef
18.
go back to reference Darai E, Fauvet R, Uzan C, et al. Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options. Hum Reprod Update. 2013;19:151–66.CrossRef Darai E, Fauvet R, Uzan C, et al. Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options. Hum Reprod Update. 2013;19:151–66.CrossRef
19.
go back to reference Chen X, Fang C, Zhu T, et al. Identification of factors that impact recurrence in patients with borderline ovarian tumors. J Ovarian Res. 2017;10:017–0316.CrossRef Chen X, Fang C, Zhu T, et al. Identification of factors that impact recurrence in patients with borderline ovarian tumors. J Ovarian Res. 2017;10:017–0316.CrossRef
20.
go back to reference Cusido M, Balaguero L, Hernandez G, et al. Results of the national survey of borderline ovarian tumors in Spain. Gynecol Oncol. 2007;104:617–22.CrossRef Cusido M, Balaguero L, Hernandez G, et al. Results of the national survey of borderline ovarian tumors in Spain. Gynecol Oncol. 2007;104:617–22.CrossRef
21.
go back to reference Shih KK, Zhou Q, Huh J, et al. Risk factors for recurrence of ovarian borderline tumors. Gynecol Oncol. 2011;120:480–4.CrossRef Shih KK, Zhou Q, Huh J, et al. Risk factors for recurrence of ovarian borderline tumors. Gynecol Oncol. 2011;120:480–4.CrossRef
22.
go back to reference du Bois A, Ewald-Riegler N, de Gregorio N, et al. Borderline tumours of the ovary: a cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie (AGO) study group. Eur J Cancer. 2013;49:1905–14.CrossRef du Bois A, Ewald-Riegler N, de Gregorio N, et al. Borderline tumours of the ovary: a cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie (AGO) study group. Eur J Cancer. 2013;49:1905–14.CrossRef
23.
go back to reference Park JY, Kim DY, Kim JH, et al. Surgical management of borderline ovarian tumors: the role of fertility-sparing surgery. Gynecol Oncol. 2009;113:75–82.CrossRef Park JY, Kim DY, Kim JH, et al. Surgical management of borderline ovarian tumors: the role of fertility-sparing surgery. Gynecol Oncol. 2009;113:75–82.CrossRef
24.
go back to reference Uzan C, Muller E, Kane A, et al. Prognostic factors for recurrence after conservative treatment in a series of 119 patients with stage I serous borderline tumors of the ovary. Ann Oncol. 2014;25:166–71.CrossRef Uzan C, Muller E, Kane A, et al. Prognostic factors for recurrence after conservative treatment in a series of 119 patients with stage I serous borderline tumors of the ovary. Ann Oncol. 2014;25:166–71.CrossRef
25.
go back to reference Koskas M, Uzan C, Gouy S, et al. Fertility determinants after conservative surgery for mucinous borderline tumours of the ovary (excluding peritoneal pseudomyxoma). Hum Reprod. 2011;26:808–14.CrossRef Koskas M, Uzan C, Gouy S, et al. Fertility determinants after conservative surgery for mucinous borderline tumours of the ovary (excluding peritoneal pseudomyxoma). Hum Reprod. 2011;26:808–14.CrossRef
26.
go back to reference Morice P, Uzan C, Fauvet R, et al. Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. Lancet Oncol. 2012;13:e103–15.CrossRef Morice P, Uzan C, Fauvet R, et al. Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. Lancet Oncol. 2012;13:e103–15.CrossRef
27.
go back to reference Alvarez RM, Vazquez-Vicente D. Fertility sparing treatment in borderline ovarian tumours. Ecancermedicalscience. 2015;9:507.CrossRef Alvarez RM, Vazquez-Vicente D. Fertility sparing treatment in borderline ovarian tumours. Ecancermedicalscience. 2015;9:507.CrossRef
28.
go back to reference Vasconcelos I, de Sousa Mendes M. Conservative surgery in ovarian borderline tumours: a meta-analysis with emphasis on recurrence risk. Eur J Cancer. 2015;51:620–31.CrossRef Vasconcelos I, de Sousa Mendes M. Conservative surgery in ovarian borderline tumours: a meta-analysis with emphasis on recurrence risk. Eur J Cancer. 2015;51:620–31.CrossRef
29.
go back to reference Camatte S, Morice P, Pautier P, et al. Fertility results after conservative treatment of advanced stage serous borderline tumour of the ovary. BJOG. 2002;109:376–80.CrossRef Camatte S, Morice P, Pautier P, et al. Fertility results after conservative treatment of advanced stage serous borderline tumour of the ovary. BJOG. 2002;109:376–80.CrossRef
30.
go back to reference Palomba S, Falbo A, Del Negro S, et al. Ultra-conservative fertility-sparing strategy for bilateral borderline ovarian tumours: an 11-year follow-up. Hum Reprod. 2010;25:1966–72.CrossRef Palomba S, Falbo A, Del Negro S, et al. Ultra-conservative fertility-sparing strategy for bilateral borderline ovarian tumours: an 11-year follow-up. Hum Reprod. 2010;25:1966–72.CrossRef
31.
go back to reference Morice P, Camatte S, Rey A, et al. Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann Oncol. 2003;14:592–8.CrossRef Morice P, Camatte S, Rey A, et al. Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann Oncol. 2003;14:592–8.CrossRef
32.
go back to reference Rice LW, Berkowitz RS, Mark SD, et al. Epithelial ovarian tumors of borderline malignancy. Gynecol Oncol. 1990;39:195–8.CrossRef Rice LW, Berkowitz RS, Mark SD, et al. Epithelial ovarian tumors of borderline malignancy. Gynecol Oncol. 1990;39:195–8.CrossRef
33.
go back to reference Song T, Choi CH, Park HS, et al. Fertility-sparing surgery for borderline ovarian tumors: oncologic safety and reproductive outcomes. Int J Gynecol Cancer. 2011;21:640–6.CrossRef Song T, Choi CH, Park HS, et al. Fertility-sparing surgery for borderline ovarian tumors: oncologic safety and reproductive outcomes. Int J Gynecol Cancer. 2011;21:640–6.CrossRef
Metadata
Title
The impact of clinicopathologic and surgical factors on relapse and pregnancy in young patients (≤40 years old) with borderline ovarian tumors
Authors
Chenyan Fang
Lingqin Zhao
Xi Chen
Aijun Yu
Liang Xia
Ping Zhang
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4932-2

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine